AstraZeneca has an active research programme to discover and develop novel treatments for diseases of the lungs and airways, such as asthma, chronic obstructive pulmonary disease (COPD) and other less prevalent disorders.
Many challenges remain in respiratory medicine, such as the development of novel drugs that interfere with the underlying disease processes, and the improvement of existing medications and delivery devices to simplify disease management for the patient. Already a leader in the treatment of asthma, AstraZeneca is expanding its range by developing novel treatments in other areas of inflammatory disease areas such as rheumatology.
Key areas of partnering interest
Respiratory
COPD and Asthma
- Advanced clinical programmes
- Early stage alliances focused on:
- Control of exacerbations – targets: inflammation, rhinovirus
- Muscle wasting and dysfunction
- Facilitating lung recovery – targets: inflammation, mucus destruction, remodelling
Novel inhalation approaches or other delivery concepts
Inflammation
Rheumatology
- Agents in clinical development with patient efficacy data that are differentiated from marketed products, specifically in rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
- Early stage alliances in rheumatology
Contacts
Lena Mårtensson, Pre-clinical
Pontus Nilsson, Clinical – respiratory
E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names
- Replace å with a
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
